Floatz logo

89zr-mmot0530a

Adnexal Diseases

University Medical Center GroningenradiopharmaceuticalPhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Adnexal Diseases cohort.

Asset / SponsorPhaseRating
Cyclobenzaprine
Christiana Care Health Services
Phase 4B
DEXAMETHASONE
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Phase 2B
Trabectedin
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Phase 2B
Olaparib
Xiaoxiang Chen
Phase 2CCC
Niraparib
Xiaoxiang Chen
Phase 2CCC
Catequentinib
Xiaoxiang Chen
Phase 2CCC

Same molecule, other indications

89zr-mmot0530a is also rated in:

digestive system neoplasmDormant
CC
Indicative ·
47 / 100
View asset →
digestive system disorderDormant
CC
Indicative ·
47 / 100
View asset →
ovarian disorderDormant
CC
Indicative ·
46 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →